RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models-Reference-Cited by-同舟云学术

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models

Published:2018-09-11 Issue:71 Volume:9 Page:33446-33458
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wong Oi Kwan¹²,Tran Thomas-Toan¹³,Ho Wei-Hsien¹⁴,Casas Meritxell Galindo¹⁵,Au Melinda¹²,Bateman Marjorie¹,Lindquist Kevin C.¹,Rajpal Arvind¹⁶,Shelton David L.¹,Strop Pavel¹⁶,Liu Shu-Hui¹⁷

Affiliation:

1. Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA

2. Allogene Therapeutics, South San Francisco, CA, USA

3. NGM Biopharmaceuticals, South San Francisco, CA, USA

4. Alector Inc., South San Francisco, CA, USA

5. acib GmbH Graz, Graz, Austria

6. Bristol-Myers Squibb, Redwood City, CA, USA

7. Abmart Inc., Redwood City, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway;International Journal of Biological Macromolecules;2024-10

2. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

3. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models;International Journal of Molecular Sciences;2024-02-05

4. Antibody drug conjugates: hitting the mark in pancreatic cancer?;Journal of Experimental & Clinical Cancer Research;2023-10-25

5. Fc-engineered monoclonal antibodies to reduce off-target liver uptake;EJNMMI Research;2023-09-11